TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03219268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 1 mg
Description: 1 mg IV every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 3 mg
Description: 3 mg IV every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 10 mg
Description: 10 mg IV every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 30 mg
Description: 30 mg IV every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 120 mg
Description: 120 mg IV every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 300 mg
Description: 300 mg IV every other wee

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 400 mg
Description: 400 mg IV every other wee

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 600 mg
Description: 600 mg IV every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 600 mg
Description: 600 mg IV every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 600 mg
Description: 600 mg IV every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 800 mg
Description: 800 mg IV every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tebotelimab 1200 mg
Description: 1200 mg IV every other week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: margetuximab
Description: 15 mg/kg IV every 3 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: margetuximab
Description: 15 mg/kg IV every 3 weeks
Study: NCT04116528

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: 0.5mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine (0.2-0.8mg/day) or Placebo orally dissolving tablet
Study: NCT00626158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
Study: NCT01073215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Lifestyle Modification
Description: The Self-Guided condition will receive the same manual content and recommendations for eating and physical activity as the Group Condition. Since this approach is primarily home-based, participants in this condition will also receive additional tips and guidelines to assist the family in following the program at home. There will be 6 visits with the health coach at weeks 01, 04, 08, 24, 40, and 52. Participants will receive 2 phone calls from health coach at weeks 16 and 32. Parents and teens will be encouraged to hold weekly meetings at home to discuss program goals and progress.
Study: NCT04116528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: Buprenorphine or Placebo orally dissolving tablet
Study: NCT03254953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitoring of body weight
Description: - weigh daily for 3 months and track their weight using the MyFitnessPal mobile app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitoring of body weight
Description: - weigh daily for 3 months and track their weight using the MyFitnessPal mobile app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitoring of diet
Description: * track their diet (food and drinks) daily using the MyFitnessPal mobile app~* when they are asked to track diet will vary based on the arm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitoring of diet
Description: * track their diet (food and drinks) daily using the MyFitnessPal mobile app~* when they are asked to track diet will vary based on the arm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-monitoring of diet
Description: * track their diet (food and drinks) daily using the MyFitnessPal mobile app~* when they are asked to track diet will vary based on the arm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weekly personalized feedback + lessons + action plans
Description: - these are additional evidence-based intervention components

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weekly personalized feedback + lessons + action plans
Description: - these are additional evidence-based intervention components
Study: NCT03545373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin tablets taken orally
Study: NCT03772951

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation Therapy
Description: Through computer information technology, using error-free, procedural learning, speech enhancement and a series of targeted computer programmatic cognitive correction tasks, patients can gradually improve problem solving and information processing capabilities, thereby improving their recognition function.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clozapine
Description: the course of disease is more than 2 years, the condition is stable for more than one month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine
Description: the course of disease is more than 2 years, the condition is stable for more than one month
Study: NCT04296474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK Alutard 5-grasses and birch
Description: Intralymphatic injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALK Diluent
Description: intralymphatic injections
Study: NCT03661034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaSense Stimulation System (non-invasive, non-significant risk)
Description: Non-invasive, non-significant risk audio-visual sensory stimulation device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaSense Stimulation System (non-invasive, non-significant risk)
Description: Non-invasive, non-significant risk audio-visual sensory stimulation device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaSense Stimulation System (non-invasive, non-significant risk)
Description: Non-invasive, non-significant risk audio-visual sensory stimulation device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaSense Stimulation System (non-invasive, non-significant risk)
Description: Non-invasive, non-significant risk audio-visual sensory stimulation device
Study: NCT04015115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Opioid Recovery Support service model
Description: see arm 1 description
Study: NCT03697980

Intervention type: DEVICE
Intervention: HeartWare Ventricular Assist Device
Description: The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
Study: NCT00308087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks
Study: NCT01679236

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Training for Smokers
Description: The provides the Mindfulness Training for Smokers intervention (7 weeks long).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Learning for Smokers
Description: This provides the Interactive Learning for Smokers intervention (7 weeks long).
Study: NCT04221282

Intervention type: DRUG
Intervention: Zebinix
Description: ESL will be initiated by the investigator in patients as a first line monotherapy or adjunctive therapy. ESL will be prescribed according to the usual care. Posology and method of administration of ESL are defined by the summary of product characteristics. Then, data on the efficacy of ESL will be collected.
Study: NCT02041247

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAC-3S
Description: VAC-3S is administered via intra-muscular route in the arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAC-3S
Description: VAC-3S is administered via intra-muscular route in the arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VAC-3S
Description: VAC-3S is administered via intra-muscular route in the arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VAC-3S
Description: VAC-3S is administered via intra-muscular route in the arm.
Study: NCT02835456

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sharklet Catheter insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone Foley Catheter insertion
Study: NCT01073215

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-Based Lifestyle Modification Program
Description: The Group condition will consist of a comprehensive family based lifestyle modification program of 23 visits (8 weekly, 8 bi-weekly, 7 monthly).~Intervention visits include a combination of 17 group sessions and 6 individual meetings with health coach. There will be 7 phone calls two weeks after each monthly visit. Adolescents and their parents attend concurrent group meetings. The content of the sessions will include topics related to nutrition, physical activity, and behavior modification for weight management.
Study: NCT02706834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 oral solution
Study: NCT00308087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks
Study: NCT01992653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
Study: NCT02706834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 oral solution
Study: NCT03452384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, the inserted needles were affixed with adhesive tapes so that real acupuncture procedure will be identical to control acupuncture procedure. For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, the inserted needles were affixed with adhesive tapes so that real acupuncture procedure will be identical to control acupuncture procedure. For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998).
Study: NCT01053962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-304 0.3 mg
Description: SP-304 0.3 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-304 1.0 mg
Description: SP-304 1.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-304 3.0 mg
Description: SP-304 3.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-304 9.0 mg
Description: SP-304 9.0 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04476953

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo looks exactly like the study drug, but it contains no active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: \~20 mg/kg/day oral, NG or D tube course for 2 consecutive days
Study: NCT01469832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MA09-hRPE
Description: * Cohort 1 50,000 cells~* Cohort 2 100,000 cells~* Cohort 2a Better Vision 100,000 cells~* Cohort 3 150,000 cells~* Cohort 4 200,000 cells
Study: NCT02706834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-828
Description: TAK-828 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-828 placebo-matching oral solution
Study: NCT04427163

Intervention type: GENETIC
Intervention: Blood sample analysis
Description: Nucleic acids sequencing, presence of proteins and metabolites.

Intervention type: OTHER
Intervention: Health status
Description: Health status will be examined by a physician and subject will complete a health status questionnaire.

Intervention type: OTHER
Intervention: Race and ethnicity
Description: Subject will complete race and ethnicity questionnaire to make sure subjects are from the Czech population.
Study: NCT02713269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo CT-guided SSRS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal Ablation Therapy
Description: Undergo thermal ablation therapy
Study: NCT01858480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-ribose
Description: D-ribose powder for oral solution and D-ribose for injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosage form designed to mock active.
Study: NCT04278677

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: melatonin
Description: Melatonin capsules to be taken for 6 weeks
Study: NCT02254083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBT 986 BS - low
Study: NCT06618469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water-based resistance training program at moderate intensity (WMI)
Description: The training session will consist of 5-10 minutes of general warm-up (joint- mobility and aerobic exercises at low intensity); 35-40 minutes of the main part, which comprised six resistance exercises, three for upper limbs (upright rowing, incline rowing, and elbow curl) and three for lower limbs (narrow stance leg extension and flexion, hip flexion and extension, and standing hip abduction) along with coordination exercises during the active rests; and 5-10 minutes of the cool-down routine (respiratory and flexibility exercises). The participants will perform in the poll the concentric and eccentric movements of each exercise at maximal velocity during 40 seconds (equivalent to working around 10 repetitions /75% 1RM each exercise). The perceived exertion level on the OMNI-RES scale progressed from 6-7 to 8-9. The number of sets per exercise progressed from 3 to 4.
Study: NCT02254083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBT 986 BS - high

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02133482

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo solution
Study: NCT02706834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-828 placebo-matching oral solution
Study: NCT02133482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 639667
Description: oral solution BI 639667, single rising doses
Study: NCT00888758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biolimus A9
Description: 200 patients with STEMI will be treated using Biomatrix stent.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: 200 patients with STEMI will be treated with PROMUS DES.
Study: NCT01694810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% NVN1000 Topical Gel
Description: 2% NVN1000 Topical Gel once daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% NVN1000 Topical Gel
Description: 4% NVN1000 4% Topical Gel applied once daily 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8% NVN1000 Topical Gel
Description: 8% NVN1000 Topical Gel applied once daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Gel
Description: Vehicle Topical Gel applied once daily
Study: NCT03800979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib is an oral medicine in Janus kinase inhibitor 3 group which has been approved by FDA in treating Rheumatoid Arthritis. It has ability to inhibit nerve signal Interferon-ɣ and Interleukin-15 between white blood cell(WBC) and the nucleus of hair follicle cell causing the production of WBC type CD8+NKG2D+ T cell to slow down which this type of WBC is one of the cause of hair loss.
Study: NCT02851966

Intervention type: PROCEDURE
Group type: OTHER
Intervention: mTESE
Description: mTESE time may be postponed or advanced.
Study: NCT01077479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1500mg nocte for 6 months
Study: NCT00580996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water high dose
Description: water 16 oz PO x 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water tiny dose
Description: water 1 oz PO x 1
Study: NCT02706834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-828 placebo-matching oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-828 placebo-matching oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-828 placebo-matching oral solution
Study: NCT00335725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone
Description: subcutaneous injection of FSH. Starting dose: 225 IU.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follicle Stimulating Hormone
Description: subcutaneous injection of FSH. Starting dose: 225 IU.
Study: NCT01935921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01380886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental infant formula with alternate protein source
Description: experimental infant formula to be fed ad libitum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula powder
Description: powdered infant formula to be fed ad libitum
Study: NCT01024790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: 24 week group exercise class supplemented with behavioral activation strategies
Study: NCT06622343

Intervention type: DRUG
Intervention: Antivenom Serum
Description: Intravenous administration of 6000 IU of antivenom serum was given to patients envenomed by pit vipers. This treatment was based on Chinese guidelines for the management of snakebites. Additionally, patients received supportive treatments, including antibiotics to prevent infection, antihistamines for allergic reactions, and magnesium sulfate for localized swelling and pain relief.

Intervention type: DRUG
Intervention: Antivenom Serum
Description: Intravenous administration of 6000 IU of antivenom serum was given to patients envenomed by pit vipers. This treatment was based on Chinese guidelines for the management of snakebites. Additionally, patients received supportive treatments, including antibiotics to prevent infection, antihistamines for allergic reactions, and magnesium sulfate for localized swelling and pain relief.

Intervention type: PROCEDURE
Intervention: Wound Debridement
Description: Patients who did not develop necrotizing skin infections received wound management, including multiple punctures using a three-edged needle for toxin drainage, along with standard wound care and debridement as necessary to prevent infection and promote healing.

Intervention type: PROCEDURE
Intervention: Wound Debridement
Description: Patients who did not develop necrotizing skin infections received wound management, including multiple punctures using a three-edged needle for toxin drainage, along with standard wound care and debridement as necessary to prevent infection and promote healing.